These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 24766145)

  • 1. An updated review of antidepressants with marked serotonergic effects in obsessive-compulsive disorder.
    Pizarro M; Fontenelle LF; Paravidino DC; Yücel M; Miguel EC; de Menezes GB
    Expert Opin Pharmacother; 2014 Jul; 15(10):1391-401. PubMed ID: 24766145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review.
    Dell'Osso B; Nestadt G; Allen A; Hollander E
    J Clin Psychiatry; 2006 Apr; 67(4):600-10. PubMed ID: 16669725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder.
    Varigonda AL; Jakubovski E; Bloch MH
    J Am Acad Child Adolesc Psychiatry; 2016 Oct; 55(10):851-859.e2. PubMed ID: 27663940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
    Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Pharmacological Treatment of Obsessive-Compulsive Disorder.
    Pittenger C
    Psychiatr Clin North Am; 2023 Mar; 46(1):107-119. PubMed ID: 36740347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Past, present and future drugs for the treatment of obsessive-compulsive disorder.
    Marazziti D; Consoli G; Baroni S; Catena Dell'Osso M
    Curr Med Chem; 2010; 17(29):3410-21. PubMed ID: 20712565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OCD: where the serotonin selectivity story begins.
    Pigott TA
    J Clin Psychiatry; 1996; 57 Suppl 6():11-20. PubMed ID: 8647793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of clomipramine and nortriptyline in the treatment of obsessive-compulsive disorder: a double-blind, placebo-controlled trial.
    Noorbala AA; Hosseini SH; Mohammadi MR; Akhondzadeh S
    J Clin Pharm Ther; 1998 Apr; 23(2):155-9. PubMed ID: 9786103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic management of obsessive-compulsive disorder.
    Jackson CW; Morton WA; Lydiard RB
    South Med J; 1994 Mar; 87(3):310-21. PubMed ID: 8134850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic treatment of obsessive-compulsive disorder: comparative studies.
    Flament MF; Bisserbe JC
    J Clin Psychiatry; 1997; 58 Suppl 12():18-22. PubMed ID: 9393392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacotherapy for obsessive compulsive disorder in clinical practice - Data of 842 inpatients from the International AMSP Project between 1994 and 2012.
    Poppe C; Müller ST; Greil W; Walder A; Grohmann R; Stübner S
    J Affect Disord; 2016 Aug; 200():89-96. PubMed ID: 27130958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review.
    Piccinelli M; Pini S; Bellantuono C; Wilkinson G
    Br J Psychiatry; 1995 Apr; 166(4):424-43. PubMed ID: 7795913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder.
    Denys D; van der Wee N; van Megen HJ; Westenberg HG
    J Clin Psychopharmacol; 2003 Dec; 23(6):568-75. PubMed ID: 14624187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Critical analysis of controlled pharmacologic studies in obsessive compulsive disorder].
    Brochier T; Hantouche E
    Encephale; 1989; 15(3):325-33. PubMed ID: 8641159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy for obsessive-compulsive disorder.
    Hollander E; Kaplan A; Allen A; Cartwright C
    Psychiatr Clin North Am; 2000 Sep; 23(3):643-56. PubMed ID: 10986733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies.
    Llorca PM; Lançon C; Brignone M; Rive B; Salah S; Ereshefsky L; Francois C
    Curr Med Res Opin; 2014 Dec; 30(12):2589-606. PubMed ID: 25249164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on the pharmacological treatment of obsessive-compulsive disorder.
    Fontenelle LF; Nascimento AL; Mendlowicz MV; Shavitt RG; Versiani M
    Expert Opin Pharmacother; 2007 Apr; 8(5):563-83. PubMed ID: 17376013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.
    Pallanti S; Quercioli L; Bruscoli M
    J Clin Psychiatry; 2004 Oct; 65(10):1394-9. PubMed ID: 15491244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of serotonergic drugs: focus on OCD.
    Marazziti D; Avella MT; Basile L; Mucci F; Dell'Osso L
    Expert Opin Drug Metab Toxicol; 2019 Apr; 15(4):261-273. PubMed ID: 30793987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.